Stockreport

Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD [Yahoo! Finance]

lululemon athletica inc.  (LULU) 
Last lululemon athletica inc. earnings: 3/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.lululemon.com
PDF - Lead program, EPI-321, is the first clinical application of epigenetic modulation in neuromuscular diseases, with a first-in-human trial in New Zealand to commence in [Read more]